PAP动态监测血浆cfDNA在进展期非小细胞肺癌患者治疗中的应用

Xu Xiaoyan,Yan Zhao,Wang Yumeng,Meng Zhaoting,Chen Jinliang,Wang Qingshan,Lin Li,Su Yudong,Ding Shaofeng,Zhu Lin,Chen Peng

Chinese Journal of Clinical Oncology（2018）

Cited 0|Views7

No score

Abstract

目的:探讨焦磷酸化激活聚合反应(pyrophosphorolysis-activated polymerization,PAP)动态监测血浆cfDNA在进展期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者治疗中的应用.方法:收集2016年3月至2017年6月就诊的进展期NSCLC患者85例,采用PAP核酸扩增实时荧光PCR法与扩增阻滞突变系统(amplication refractory mutation system,ARMS)实时荧光PCR法检测血浆cfDNA的EGFR突变状况,比较组织与血浆及PAP法与ARMS-PCR检测结果的一致性;对突变阳性的38例患者采用PAP动态监测血浆基因突变状况.结果:血浆与组织突变检测结果差异无统计学意义(P=0.092).PAP与ARMS-PCR突变检测结果差异亦无统计学意义(P=0.210).血浆cfDNA EGFR基因突变的检出率,在疾病进展者中较未进展者中高(62.5% vs.21.3%,P<0.001).结论:PAP可用于血浆cfDNA突变检测及动态监测以提前获得疾病进展的信息.

Translated text

Key words

pyrophosphorolysis-activated polymerization(PAP),cfDNA,EGFR mutation,non-small cell lung cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined